Dr. Brahmer Discusses Second-Line Pembrolizumab in NSCLC

Julie R. Brahmer, MD
Published: Wednesday, Mar 14, 2018



Julie R. Brahmer, MD, associate professor of oncology, co-director of the Upper Aerodigestive Department, Bloomberg Kimmel Institute for Cancer Immunotherapy, Johns Hopkins Medicine, discusses second-line pembrolizumab (Keytruda) in non–small cell lung cancer (NSCLC).

Data on second-line therapy with pembrolizumab after chemotherapy showed a lower response rate of approximately 21%. Brahmer suggests that receiving chemotherapy before pembrolizumab may not be beneficial, particularly for patients who express high levels of PD-L1.

Many in the field are moving away from single-agent pembrolizumab, says Brahmer, specifically in the treatment of patients with nonsquamous cell histologies. However, cohort G of the KEYNOTE-021 study showed higher response rates with the combination of pembrolizumab, carboplatin and pemetrexed compared with carboplatin and pemetrexed alone in NSCLC.
SELECTED
LANGUAGE


Julie R. Brahmer, MD, associate professor of oncology, co-director of the Upper Aerodigestive Department, Bloomberg Kimmel Institute for Cancer Immunotherapy, Johns Hopkins Medicine, discusses second-line pembrolizumab (Keytruda) in non–small cell lung cancer (NSCLC).

Data on second-line therapy with pembrolizumab after chemotherapy showed a lower response rate of approximately 21%. Brahmer suggests that receiving chemotherapy before pembrolizumab may not be beneficial, particularly for patients who express high levels of PD-L1.

Many in the field are moving away from single-agent pembrolizumab, says Brahmer, specifically in the treatment of patients with nonsquamous cell histologies. However, cohort G of the KEYNOTE-021 study showed higher response rates with the combination of pembrolizumab, carboplatin and pemetrexed compared with carboplatin and pemetrexed alone in NSCLC.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Advances in™ Therapies for Patients With ALK-Positive Lung Cancers: More Options…More Decisions…Better OutcomesAug 30, 20191.5
Oncology Briefings™: Treating Advanced NSCLC Without Actionable MutationsAug 30, 20191.0
Publication Bottom Border
Border Publication
x